- By Stephany Tandy-Connor, MS
- Posted May 4, 2017
Direct-to-Consumer Genetic Testing: Taking the Trend to the Next Level…Responsibly
Our DNA tells a story — it tells us who we are. With advancements in genetic testing and an increased awareness in personalized healthcare, interest in direct-to-consumer (DTC) testing is on the rise. DTC genetic testing companies have made limited genetic testing for the general population readily accessible to healthy individuals. However,…
- By Deepti Babu, MS, CGC
- Posted April 24, 2017
Piece by Piece: Exome Sequencing Helps Solve the Autism Puzzle
Autism spectrum disorders (ASDs) are neurodevelopmental disorders (NDDs) seen in 1-2% of children; symptoms and severity differ widely1,2,3, so they can be difficult to diagnose. ASDs can be inherited and involve numerous genes, which creates a challenge for single gene testing. How can genetic testing help children and families, if the child…
- By Jackie Connor
- Posted April 17, 2017
AmbryShare Extends Cohort Invite to Autism Clinicians and their Patients
Accurate genetic testing can help clinicians provide more individualized treatments for their patients, and the more genetic information a researcher has access to, the more targeted treatments can be developed. {Read: “For Your Breast Cancer Practice: Data From More Than 60,000 Refines Predisposition Gene Risks”} In March 2016, Ambry’s…
- By Deepti Babu, MS, CGC
- Posted April 14, 2017
Ambry Genetics and Leading Academic Researchers Collaborate to Improve Knowledge of Genetic Risk Factors for Breast Cancer
New clinical evidence collected from >65,000 women with breast cancer demonstrates 83% of positive test results are found in genes that impact clinical management Multi-gene germline genetic testing allows for efficient analysis, maximizing risk assessment while minimizing the time needed for results. This has been particularly effective…
- By Deepti Babu, MS, CGC
- Posted April 10, 2017
Can Patients with Hematological Cancer Have Genetic Testing?
The short answer is: Genetic testing is possible, but depends on other factors. The question of whether genetic testing is possible for patients with a history of hematological cancer comes up often in the clinical setting and in the testing laboratory. This makes sense since genetic testing is performed on DNA isolated from white blood cells…
- By Deepti Babu, MS, CGC
- Posted April 3, 2017
Current Genetic Testing Guidelines Miss Some Families with CDH1 Mutations
Hereditary diffuse gastric cancer (HDGC) is an inherited cancer syndrome caused by CDH1 gene mutations. It occurs most frequently in Japan and eastern Asia; current incidence in the U.S. is estimated at 10-40 individuals per 100,000.1 Individuals with mutations in the CDH1 gene have up to an 80% lifetime risk of diffuse gastric…
- By Jackie Connor
- Posted March 31, 2017
Ambry Experts Provide Insight on Genetic Testing’s Clinical Utility at the 2017 SSO Annual Cancer Symposium
Ambry has continued to provide clinicians with the most relevant and useful information to encourage education about the benefits of genetic testing for patients and ways to streamline genetic testing in clinical practice. At the 2017 SSO Annual Cancer Symposium, Ambry hosted the presentation “On the Cutting Edge: Sharpening Your Genetic Awareness…
- By Jackie Connor
- Posted March 30, 2017
Ambry Talks Plans for Personalized Genomic Test Launch, Third Annual Trivia Night a Hit
On Thursday evening, March 23rd, an audience of more than 100 genetic counselors and geneticists from across the United States listened to Ambry Genetics’ Clinical Genomics Marketing Manager Layla Shahmirzadi, MS, CGC, discuss plans to launch a personalized genomic test for healthy individuals. The talk took place at Events on Jackson venue…
- By Jackie Connor
- Posted March 30, 2017
Dr. Rachid Karam Discusses Variant Classification at 2017 ACMG Annual Meeting
Actionable medical results are often a key component in deciding a patient’s medical management and specialized treatment options. However, some genetic test results can have unclear implications or Variants of Unknown Significance (VUS), which can often affect a clinician’s medical management plans for their patients. During the 2017 ACMG…
- By Jackie Connor
- Posted March 21, 2017
Recapping Ambry at the 2017 Annual Meeting on Women’s Cancer
Ambry experts and collaborators presented new research at this year’s Annual Meeting on Women’s Cancer. In addition to discussing GYNplus and OvaNext testing options, Ambry featured three scientific posters and a lunch presentation “Advancing Molecular Diagnostics for Gynecologic Cancer: Efforts in Data Sharing and Tumor Testing to Improve…